Immunotherapy of neonatal septicemia

Mervin Yoder, R. A. Polin

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

This chapter has reviewed the deficiencies in immune defense that place the neonate, particularly the premature infant, at increased risk of invasive bacterial disease. We also have reviewed the literature on the rationale for exchange transfusion, granulocyte transfusion, intravenous immunoglobulin, and fibronectin administration as immunotherapeutic agents in infected infants. There have been no randomized controlled trials of exchange transfusion, immunoglobulin, or fibronectin administration in human infants with infection. Granulocyte transfusion in the infected newborn infant has been studied in a controlled fashion, but the results of clinical trials are conflicting. Thus, all of these interventions appear to need further evaluation. We therefore recommend that in the septic newborn infant with neutropenia and an I/T ratio ≥ 0.8, who fails to demonstrate a favorable response to conventional antibacterial chemotherapy and cardiopulmonary support, the administration of approximately 1 x 109 irradiated granulocytes per kg may be beneficial. In the absence of equipment to isolate the granulocytes, a double-volume exchange transfusion with fresh heparinized whole blood will provide a similar quantity of functional phagocytes.

Original languageEnglish
Pages (from-to)481-501
Number of pages21
JournalPediatric Clinics of North America
Volume33
Issue number3
StatePublished - 1986

Fingerprint

Granulocytes
Immunotherapy
Sepsis
Newborn Infant
Fibronectins
Intravenous Immunoglobulins
Phagocytes
Neutropenia
Premature Infants
Immunoglobulins
Randomized Controlled Trials
Clinical Trials
Drug Therapy
Equipment and Supplies
Infection

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Immunotherapy of neonatal septicemia. / Yoder, Mervin; Polin, R. A.

In: Pediatric Clinics of North America, Vol. 33, No. 3, 1986, p. 481-501.

Research output: Contribution to journalArticle

Yoder, M & Polin, RA 1986, 'Immunotherapy of neonatal septicemia', Pediatric Clinics of North America, vol. 33, no. 3, pp. 481-501.
Yoder, Mervin ; Polin, R. A. / Immunotherapy of neonatal septicemia. In: Pediatric Clinics of North America. 1986 ; Vol. 33, No. 3. pp. 481-501.
@article{5efc2acdc83d46e58d8d00430816e9a7,
title = "Immunotherapy of neonatal septicemia",
abstract = "This chapter has reviewed the deficiencies in immune defense that place the neonate, particularly the premature infant, at increased risk of invasive bacterial disease. We also have reviewed the literature on the rationale for exchange transfusion, granulocyte transfusion, intravenous immunoglobulin, and fibronectin administration as immunotherapeutic agents in infected infants. There have been no randomized controlled trials of exchange transfusion, immunoglobulin, or fibronectin administration in human infants with infection. Granulocyte transfusion in the infected newborn infant has been studied in a controlled fashion, but the results of clinical trials are conflicting. Thus, all of these interventions appear to need further evaluation. We therefore recommend that in the septic newborn infant with neutropenia and an I/T ratio ≥ 0.8, who fails to demonstrate a favorable response to conventional antibacterial chemotherapy and cardiopulmonary support, the administration of approximately 1 x 109 irradiated granulocytes per kg may be beneficial. In the absence of equipment to isolate the granulocytes, a double-volume exchange transfusion with fresh heparinized whole blood will provide a similar quantity of functional phagocytes.",
author = "Mervin Yoder and Polin, {R. A.}",
year = "1986",
language = "English",
volume = "33",
pages = "481--501",
journal = "Pediatric Clinics of North America",
issn = "0031-3955",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Immunotherapy of neonatal septicemia

AU - Yoder, Mervin

AU - Polin, R. A.

PY - 1986

Y1 - 1986

N2 - This chapter has reviewed the deficiencies in immune defense that place the neonate, particularly the premature infant, at increased risk of invasive bacterial disease. We also have reviewed the literature on the rationale for exchange transfusion, granulocyte transfusion, intravenous immunoglobulin, and fibronectin administration as immunotherapeutic agents in infected infants. There have been no randomized controlled trials of exchange transfusion, immunoglobulin, or fibronectin administration in human infants with infection. Granulocyte transfusion in the infected newborn infant has been studied in a controlled fashion, but the results of clinical trials are conflicting. Thus, all of these interventions appear to need further evaluation. We therefore recommend that in the septic newborn infant with neutropenia and an I/T ratio ≥ 0.8, who fails to demonstrate a favorable response to conventional antibacterial chemotherapy and cardiopulmonary support, the administration of approximately 1 x 109 irradiated granulocytes per kg may be beneficial. In the absence of equipment to isolate the granulocytes, a double-volume exchange transfusion with fresh heparinized whole blood will provide a similar quantity of functional phagocytes.

AB - This chapter has reviewed the deficiencies in immune defense that place the neonate, particularly the premature infant, at increased risk of invasive bacterial disease. We also have reviewed the literature on the rationale for exchange transfusion, granulocyte transfusion, intravenous immunoglobulin, and fibronectin administration as immunotherapeutic agents in infected infants. There have been no randomized controlled trials of exchange transfusion, immunoglobulin, or fibronectin administration in human infants with infection. Granulocyte transfusion in the infected newborn infant has been studied in a controlled fashion, but the results of clinical trials are conflicting. Thus, all of these interventions appear to need further evaluation. We therefore recommend that in the septic newborn infant with neutropenia and an I/T ratio ≥ 0.8, who fails to demonstrate a favorable response to conventional antibacterial chemotherapy and cardiopulmonary support, the administration of approximately 1 x 109 irradiated granulocytes per kg may be beneficial. In the absence of equipment to isolate the granulocytes, a double-volume exchange transfusion with fresh heparinized whole blood will provide a similar quantity of functional phagocytes.

UR - http://www.scopus.com/inward/record.url?scp=0022515783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022515783&partnerID=8YFLogxK

M3 - Article

C2 - 3520460

AN - SCOPUS:0022515783

VL - 33

SP - 481

EP - 501

JO - Pediatric Clinics of North America

JF - Pediatric Clinics of North America

SN - 0031-3955

IS - 3

ER -